

Antifungal Resistance in Patients with Candidemia: A Retrospective Cohort Study

Namareq Aldardeer (✉ aldardeem@hotmail.com)

King Faisal Specialist Hospital and Research Centre - Jeddah <https://orcid.org/0000-0001-9323-1606>

Hadiel Albar

King Faisal Specialist Hospital and Research Center

Majda Al-Attas

King Faisal Specialist Hospital and Research Center

Abdelmoneim Eldali

King Faisal Specialist Hospital and Research Center

Mohammed Qutub

King Faisal Specialist Hospital and Research Center

Ashraf Hassanien

Pfizer Inc

Basem Alraddadi

King Faisal Specialist Hospital and Research Center

Research article

Keywords: Antifungal Resistance, Epidemiology, Risk Factors, Candida parapsilosis, Mortality, Fluconazole Resistance

Posted Date: December 19th, 2019

DOI: <https://doi.org/10.21203/rs.2.9663/v4>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on January 17th, 2020. See the published version at <https://doi.org/10.1186/s12879-019-4710-z>.

Abstract

Background: Candidaemia is the most common form of invasive candidiasis. Resistant Candida blood stream infection (BSI) is rising, with limitations on the development of broader-spectrum antifungal agents worldwide. Our study aimed to identify the occurrence of antifungal-resistant candidaemia and the distribution of these species, determine the risk factors associated with antifungal resistance and evaluate the association of antifungal-resistant candidaemia with the length of intensive care unit (ICU) and hospital stay and with 30-day mortality. **Methods:** A retrospective cohort study was conducted at King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia. Adult patients diagnosed with candidaemia from January 2006 to December 2017 were included. **Results:** A total of 196 BSIs were identified in 94 males (49.74%) and 95 females (50.26%). *C. glabrata* was the most commonly isolated Candida species, with 59 (30%), followed by *C. albicans* with 46 (23%). Susceptibility data were available for 122/189 patients, of whom 26/122 (21%) were resistant to one or more antifungals. *C. parapsilosis* with available sensitivity data were found in 30/122 isolates, of which 10/30 (33%) were resistant to fluconazole. Risk factors significantly associated with antifungal-resistant candidaemia included previous echinocandin exposure (odds ratio (OR) =1.38; 95% confidence interval (CI) (1.02-1.85); P= 0.006) and invasive ventilation (OR=1.3; 95% CI (1.08-1.57); P= 0.005). The median length of ICU stay was 29 days [range 12 -49 days] in the antifungal-resistant group and 18 days [range 6.7-37.5 days] in the antifungal-sensitive group (P=0.28). The median length of hospital stay was 51 days [range 21-138 days] in the antifungal-resistant group and 35 days [range 17-77 days] in the antifungal-sensitive group (P=0.09). Thirty-day mortality was 15 (57.7%) and 54 (56.25%) among the antifungal-resistant and antifungal-sensitive groups, respectively (OR=1.01; 95% CI (0.84-1.21); P= 0.89). **Conclusions:** Our results indicate a high frequency of non- *C. albicans* candidaemia. The rise in *C. parapsilosis* resistance to fluconazole is alarming. Further studies are required to confirm this finding

Background

Systemic fungal infections have emerged as a significant public health problem (1). Among hospitalized patients, candidaemia is the most common form of invasive candidiasis (IC), which accounts for 9% of all nosocomial bloodstream infections (BSIs) (2, 3). In a 2014 United States (US) surveillance study, *Candida* species ranked as the seventh causative organism of healthcare-associated BSIs (4). Recent reports indicated that candidaemia is the third or fourth most common hospital-acquired BSI in US hospitals (5). *Candida* species are considered the leading pathogen in many fungal infections affecting humans. Among 15 distinct *Candida* species causing human disease, *C. albicans*, *C. glabrata*, *C. tropicalis*, *C. parapsilosis* and *C. krusei* are the most common pathogens leading to IC (5).

Risk factors associated with antifungal resistance have been addressed in many studies. Previous fluconazole exposure, neutropenia and chronic kidney disease are known to contribute to *C. albicans* fluconazole resistance (6). However, total parental nutrition, previous episodes of candidaemia and the presence of fluconazole-resistant isolates were mainly accompanied by echinocandin resistance (7). In Saudi Arabia, many studies have described the distribution and risk factors for *Candida* BSI; however,

there are no local studies on the risk factors associated with antifungal resistance and its effect on mortality. *C. albicans* were the most commonly isolated *Candida* among all studies conducted in Saudi Arabia (8, 9) (10, 11). Predisposing factors related to candidaemia occurrence were related to use of a central venous catheter, previous use of broad-spectrum antibiotics and complicated abdominal surgeries; the mortality rate was 43% for all candidaemia cases (9). Therefore, our study was conducted to identify the occurrence of antifungal-resistant candidaemia, describe the distribution of *Candida* species among hospitalized patients with candidaemia, determine the risk factors associated with antifungal resistance and evaluate the association of antifungal resistance with length of ICU and hospital stay and with 30-day mortality.

Methods

Setting and study design

A retrospective cohort study was conducted at King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia (KFSH&RC-J), a 500-bed teaching and tertiary care hospital. The study was approved by the hospital institutional review board. Between January 2006 and December 2017, all adult patients 18 years old and above with isolated *Candida* BSI with or without other forms of IC were included. IC included disseminated hepatosplenic candidiasis, intra-abdominal candidiasis, *Candida* intravascular infection, osteoarticular candidiasis, *Candida* endophthalmitis, vulvovaginal candidiasis, *Candida* urinary tract infection, oropharyngeal candidiasis, oesophageal candidiasis or central nervous system candidiasis (5). The study excluded patients under 18 years of age and those infected with IC alone in the absence of candidaemia. Patients with candidaemia were reviewed through hospital electronic charts. The REDCap system was used to collect patient information, such as patient demographics and comorbidities. Baseline characteristics and *Candida* distribution were assessed for all patients with *Candida* BSI. Patients with available susceptibility data were divided into two groups: antifungal-sensitive and antifungal-resistant; risk factor and mortality analyses were performed. Antifungal resistance was considered for any identified isolate with resistance to one or more antifungals based on the laboratory cut-off value of minimum inhibitory concentration (MIC).

The primary outcome was the occurrence of antifungal resistance among candidaemia patients over a twelve-year study period. The secondary outcomes were the distribution of *Candida* BSI, the risk factors for antifungal resistance and the association of antifungal resistance with length of ICU and hospital stay and with 30-day mortality.

Microbiology

The identification of *Candida* BSI was consistent throughout the study period. Identification was performed by a blood culture test and processed by using the automated blood culture system BACTEC FX. The average incubation period was five days and reaches up to 21 days whenever candidaemia is suspected. The API 20C AUX Kit was used for identification and specification of yeast, and Sensititre YeastOne was used for susceptibility. The MICs for fluconazole, voriconazole, itraconazole,

posaconazole, amphotericin B, flucytosine, caspofungin, anidulafungin and micafungin were interpreted based on the Clinical and Laboratory Standard Institute (CLSI M27-S4). As the interpretation of the amphotericin B susceptibility breakpoint has not yet been defined (12), our study did not address amphotericin B susceptibility testing for *Candida* BSI.

Statistical analysis

Data were analysed using SAS version 9.4. Descriptive statistics using the mean, median and interquartile range (IQR) were used for continuous variables. Frequencies and percentages were used for categorical variables. The chi-square test and Fisher's exact test were used to compare categorical variables. For risk factor analysis of antifungal resistance, we performed a univariate logistic regression analysis. For 30-day mortality, we performed univariate and multivariable analyses to identify factors associated with mortality. A P value less than 0.05 was considered significant.

Results

From January 2006 to December 2017, a total of 196 *Candida* species were identified in 189 patients. Demographic characteristics and risk factors associated with resistant *Candida* BSI are listed in (Table 1). The most common *Candida* species during the study period was *C. glabrata* (n= 59, 30.1%). Distributions of *Candida* species are included in (Table 2). Table

One hundred and twenty-two patients with antifungal susceptibility data were analysed in the candidaemia resistance risk factor analysis (Table 3); the percentage of antifungal resistance was 21% (26/122). Candidaemia with antifungal resistance was significantly more likely to develop among patients with previous echinocandin exposure (odds ratio (OR), 1.38; 95% CI (1.02-1.85); P= 0.006) and in patients who received invasive ventilation (OR, 1.3; 95% CI (1.08-1.57); P= 0.005).

Cross-resistance among azole antifungals was observed in our study. All strains resistant to voriconazole, including five strains of *C. albicans*, two strains of *C. parapsilosis* and one strain of *C. tropicalis*, were also resistant to fluconazole. Only two isolates were resistant to caspofungin, and three isolates were resistant to anidulafungin (Supplementary appendix Table 1 and 2).

The median (interquartile range [IQR]) length of ICU stay was 29 days [range 12-49 days] in the antifungal-resistant group and 18 days [range 6.7-37.5 days] in the antifungal-sensitive group (P=0.28). The median [IQR] length of hospital stay was 51 days [range 21-138 days] in the antifungal-resistant group and 35 days [range 17-77 days] in the antifungal-sensitive group (P=0.09). Thirty-day mortality was 15 (57.7%) and 54 (56.25%) for the antifungal-resistant and antifungal-sensitive groups, respectively [OR=1.01; 95% CI (0.84-1.21); P= 0.89] (Table 4). **e 4**

In a multivariate logistic regression analysis used to assess factors associated with mortality in patients with candidaemia, the following factors were independently associated with mortality. Liver cirrhosis [OR=5.36; 95% CI (1.14-25.1)], non-haematological malignancy [OR=2.3; 95% CI (1.01-5.25)],

blood/platelet transfusion [OR=4.4; 95% CI (1.98-9.7)], central venous catheter [OR=4.37; 95% CI (1.79-10.66)] and invasive ventilation [OR=3.88; 95% CI (1.82-8.29)] (Supplementary appendix Table S3).

We performed a secondary analysis for patients with fluconazole-resistant *C. parapsilosis* to identify risk factors for resistance. Univariate analysis revealed that echinocandin exposure [OR=12.8; 95% CI (2.01-81.10)], blood/platelet transfusion [OR=14.6; 95% CI (1.54-138.18)] and invasive ventilation [OR=2.1; 95% CI (1.31-3.39)] were associated with fluconazole-resistant *C. parapsilosis* (Table 5).

Discussion

Worldwide, there has been a notable shift away from *C. albicans* among patients with *Candida* BSI (13). Our study showed a high frequency in non-*C. albicans* candidaemia (Figure 1). These strains had a higher cost and length of hospital stay than *C. albicans* (14). *C. glabrata* was the predominantly isolated *Candida* species among our candidaemia patients, representing thirty percent of cases, followed by *C. albicans* and *C. parapsilosis*. These findings differ from those of previous local studies. Two studies conducted in Saudi Arabia in a university hospital and armed force hospital between 1998 to 1999 and 1996 to 2002 concluded that *C. albicans* was the most commonly isolated *Candida* species among patients with candidaemia, followed by *C. tropicalis* and *C. parapsilosis* (8, 11). Moreover, *C. albicans* remained the dominant isolated species among candidaemia cases in many studies (1, 2, 15, 16). Geographic variation significantly affects the species distribution of *Candida* (2). A systematic review summarizing the distribution of *Candida* species found a high concentration of *C. albicans* isolates in Northern and Central Europe in addition to the USA; however, non-*C. albicans* species were more common in South America, Asia and Southern Europe (17).

Antifungal resistance is a growing primary concern for most healthcare providers. We analysed one hundred and twenty-two *Candida* BSI cases for resistance. Twenty-one percent of all isolates were resistant to one or more antifungal agents. The patient's risk of developing antifungal resistance was a primary concern in our study. We looked for many possible predisposing factors for drug insensitivity 90 days prior to a candidaemia episode. Patient's previous exposures to broad-spectrum antibiotics, antifungals and corticosteroids were reported; none of the aforementioned risk factors showed a significant association with antifungal resistance in our study despite a positive association of previous antimicrobial exposure to fluconazole resistance among candidaemia in a previous study (18). However, previous exposure to echinocandins was significantly associated with antifungal resistance among our patients. Many researchers have confirmed that decreased susceptibility to *Candida* is significantly associated with previous antifungal exposure and an inappropriate prior course of antifungal therapy (6, 19, 20). In fact, fluconazole exposure was found to be a risk factor for gene mutation and overexposure that leads to future fluconazole-resistant *C. parapsilosis* (21). Furthermore, we investigated patient comorbidities and history of invasive procedures or surgery. Many studies addressed drug-resistant candidaemia among cancer patients and considered them a high-risk group (22). However, our cohort found that antifungal resistance was low among candidaemia patients with non-haematological malignancy. On the other hand, invasive ventilation was significantly associated with drug resistance; this

result has been concluded by many researchers, who found that *Candida* resistance is dramatically higher among critical-care patients (17).

C. parapsilosis is known to have a high affinity for fluconazole, and resistance was absent in an earlier prospective trial (23). In our study, up to thirty-three percent of *C. parapsilosis* strains were insensitive to fluconazole. Clinical resistance to echinocandins is rare; however, some cases of caspofungin resistance in patients with prolonged exposure to echinocandins have been reported (13). Our study found few cases of echinocandin resistance. A 2012 US study investigated changes in the incidence of antifungal drug resistance, showing a 7% resistance to fluconazole and only 1% to echinocandin (15). In a US multicentre candidaemia surveillance programme, an increase in the rate of echinocandin resistance was mainly found in *C. glabrata*, despite it being the preferred treatment (7). Indeed, patients with fluconazole resistance were at higher risk for *C. glabrata*-associated echinocandin resistance (16). The variation in antifungal resistance patterns across geographic regions was addressed in a report on SENTRY antimicrobial surveillance, which observed a detectable resistance to anidulafungin, micafungin, and azoles among isolates of *C. glabrata* from North America (24).

Candida BSI contributed to a prolonged hospital stay and an increase in the overall healthcare cost (2). Furthermore, drug resistance was associated with overall mortality (10, 22). Despite the increase in length of hospital stay and mortality among our patients with antifungal resistance, the results were not significant.

The retrospective nature of our study could prevent us from identifying all risk factors related to our candidaemia cases. Data on source control and appropriateness of antifungal treatment in terms of timing and dosing of antifungals were not included in our study. Patients who transferred from an outside hospital had no previous records in our system, and risk factors were identified only by physician evaluation notes and nurse documentation. Another limitation is the unavailability of susceptibility data between 2006 and 2011 for all *Candida* species isolated during our study period, as the request for data was sent out and performed only upon physician request. Although KFSHRC-J is a bone marrow transplantation centre, the number of patients with haematological malignancies involved in our study was small, which prevents us from investigating fluconazole pre-exposure as a risk factor for drug-resistant candidaemia.

Conclusion

The study identified a high frequency of non-*albicans* candidaemia. The rise in fluconazole-resistant *C. parapsilosis* is alarming. More regional data from different hospital settings are needed to allow for a comparison of findings. Our study emphasizes the importance of implementation and compliance with antimicrobial stewardship programmes to control antifungal utilization among hospitalized patients.

List Of Abbreviations

BSI	Bloodstream Infection
CI	Confidence Interval
CLSI	Clinical and Laboratory Standard Institute
CRRT	Continuous Renal Replacement Therapy
GI	Gastrointestinal
HD	Haemodialysis
KFSH&RC-J	King Faisal Specialist Hospital and Research Centre, Jeddah
PD	Peritoneal Dialysis
IC	Invasive Candidiasis
ICU	Intensive Care Unit
IQR	Interquartile Range
MIC	Minimum Inhibitory Concentration
OR	Odds Ratio
TPN	Total Parental Nutrition
US	United States

Declarations

Ethics approval and consent to participate:

The study was approved by the institutional review board of King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia (IRB# 17_02).

Consent for publication

Not applicable.

Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request

Competing interests

AH works at Pfizer, anti infectives.

Funding

Pfizer Biopharmaceutical contributed in language editing and article-processing charges. There is no role for the funding body in the design of the study and collection, analysis and interpretation of data.

Authors' contributions

NA and **BA** Conception and design, data acquisition, analytical plan, interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, approval of the final version for publication, and agreement to be accountable for all aspects of the work. **HA** Conception and design, data acquisition, approval of the final version for publication, and agreement to be accountable for all aspects of the work. **AE** Conception and design, data acquisition, analytical plan, interpretation of data for the work, approval of the final version for publication, and agreement to be accountable for all aspects of the work. **MA** Critical revision of the manuscript for important intellectual content, approval of the final version for publication, and agreement to be accountable for all aspects of the work. **MQ** Critical revision of the manuscript for important intellectual content, approval of the final version for publication, and agreement to be accountable for all aspects of the work. **AH** Critical revision of the manuscript for important intellectual content, approval of the final version for publication, and agreement to be accountable for all aspects of the work.

All authors have read and approved the final manuscript

Acknowledgements

Not applicable.

References

1. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. The changing epidemiology of healthcare-associated candidemia over three decades. *Diagn Microbiol Infect Dis.* 2012;73(1):45-8.
2. Kett DH, Azoulay E, Echeverria PM, Vincent JL, Extended Prevalence of Infection in ICUSGol. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. *Crit Care Med.* 2011;39(4):665-70.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. *Clinical Infectious Diseases.* 2004;39(3):309-17.
4. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. *N Engl J Med.* 2014;370(13):1198-208.
5. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2016;62(4):e1-50.
6. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de Pipaon M, Hernandez-Caballero C, Aznar-Martin J, et al. Risk factors for fluconazole-resistant candidemia. *Antimicrob Agents*

- Chemother. 2010;54(8):3149-54.
7. Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs ZG, et al. Epidemiology and Risk Factors for Echinocandin Nonsusceptible *Candida glabrata* Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014. *Open Forum Infect Dis*. 2015;2(4):ofv163.
 8. Akbar DH, Tahawi AT. Candidemia at a University Hospital: epidemiology, risk factors and predictors of mortality. *Ann Saudi Med*. 2001;21(3-4):178-82.
 9. Al-Tawfiq JA. Distribution and epidemiology of *Candida* species causing fungemia at a Saudi Arabian hospital, 1996-2004. *Int J Infect Dis*. 2007;11(3):239-44.
 10. Al Thaqafi AH, Farahat FM, Al Harbi MI, Al Amri AF, Perfect JR. Predictors and outcomes of *Candida* bloodstream infection: eight-year surveillance, western Saudi Arabia. *Int J Infect Dis*. 2014;21:5-9.
 11. Aljasser AM EN. Distribution of *Candida* species among bloodstream isolates. *Saudi Med J*. 2004;25(5):566-9.
 12. Park BJ, Arthington-Skaggs BA, Hajjeh RA, Iqbal N, Ciblak MA, Lee-Yang W, et al. Evaluation of amphotericin B interpretive breakpoints for *Candida* bloodstream isolates by correlation with therapeutic outcome. *Antimicrob Agents Chemother*. 2006;50(4):1287-92.
 13. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. *Drugs*. 2011;71(1):11-41.
 14. Moran C, Grussemeyer CA, Spalding JR, Benjamin DK, Jr., Reed SD. Comparison of costs, length of stay, and mortality associated with *Candida glabrata* and *Candida albicans* bloodstream infections. *Am J Infect Control*. 2010;38(1):78-80.
 15. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. *Clin Infect Dis*. 2012;55(10):1352-61.
 16. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of *Candida glabrata*. *J Clin Microbiol*. 2012;50(4):1199-203.
 17. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of *albicans* and the various non-*albicans* *Candida* spp among candidemia isolates from inpatients in various parts of the world: a systematic review. *Int J Infect Dis*. 2010;14(11):e954-66.
 18. Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, et al. Antibiotic exposure as a risk factor for fluconazole-resistant *Candida* bloodstream infection. *Antimicrob Agents Chemother*. 2012;56(5):2518-23.
 19. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. *Antimicrob Agents Chemother*. 2011;55(2):532-8.
 20. Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible *Candida* species in hospitalized

- patients with candidemia. *Antimicrob Agents Chemother.* 2012;56(6):3239-43.
21. Souza AC, Fuchs BB, Pinhati HM, Siqueira RA, Hagen F, Meis JF, et al. *Candida parapsilosis* Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected *Galleria mellonella* Larvae. *Antimicrob Agents Chemother.* 2015;59(10):6581-7.
 22. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant *Candida glabrata* infection in cancer patients. *Emerg Infect Dis.* 2014;20(11):1833-40.
 23. Canton E, Peman J, Quindos G, Eraso E, Miranda-Zapico I, Alvarez M, et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of *Candida parapsilosis*, *Candida orthopsilosis*, and *Candida metapsilosis* isolated from patients with candidemia. *Antimicrob Agents Chemother.* 2011;55(12):5590-6.
 24. Pfaller MA, Diekema DJ. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. *Clinical Microbiology Reviews.* 2007;20(1):133-63.

Tables

1: Baseline characteristics for patients with candida bloodstream infection (BSIs)

Characteristics	Number of Patients (N=189) n (%)
Age (years)	57.3± 17.5
Gender	
Male	94 (49.74%)
Female	95 (50.26%)
Septicemia co-infection	79 (41.8%)
Baseline Comorbidities	
Hypertension	99 (52.38%)
Chronic kidney disease	105 (55.56%)
Chronic liver disease	24 (12.7 %)
Cirrhosis	33 (17.46%)
Cardiovascular diseases	96 (50.79%)
Respiratory diseases	52 (27.51%)
Human immunodeficiency virus	3 (1.59%)
Solid organ transplantation	8 (4.23%)
Hematological malignancy	9 (4.76%)
Solid organ malignancy	48 (25.4%)
Neutropenia *	25 (13.23%)
History of IV drug user	3 (1.59%)
Platelet transfusion	135 (71.43%)
Recent hospital admission	35 (18.52%)
Exposure to medication within 3 months *	
Broad spectrum antibiotics	182 (96.3%)
Broad spectrum antifungal	3(1.59%)
Narrow spectrum antifungal (Fluconazole)	11 (5.82%)
Echinocandins	38 (20.11%)
Corticosteroids	86 (45.5%)
Exposure to medical procedures within 3 months	20 (10.58%)
Central line insertion	151 (79.89%)
Catheter	148 (78.31%)
Mechanical Ventilation	100 (52.91%)
Surgery within 3 months	77 (40.74%)
Renal Replacement therapy	
GI	38 (49.35%)
Non- GI	39 (50.65%)
Continuous Renal Replacement therapy	66 (34.92%)
HD	54 (28.57%)
PD	4 (2.12%)
CRRT	11 (5.82%)
SLID	4 (2.12%)

parenteral nutrition (TPN); Gastrointestinal (GI); Hemodialysis (HD); Peritoneal dialysis (PD); Continuous renal replacement therapy (CRRT); Sustained low efficiency dialysis (SLID); Intravenous (IV);*Neutropenia defined as an absolute neutrophil count of, $1.0 \times 10^9/L$ or less; N=total number of patients; n=number of patients or events

Table 2: Distribution of *Candida* Species over the study period

<i>Candida</i> isolates	Total number of isolates (N=196) n(%)
<i>C. glabrata</i>	59 (30.1)
<i>C. albicans</i>	46 (23.47)
<i>C. parapsilosis</i>	38 (19.39)
<i>C. tropicalis</i>	35 (17.86)
<i>C. krusei</i>	6 (3.06)
<i>C. famata</i>	5 (2.55)
<i>C. lusitaniae</i>	1 (0.51)
<i>C. kefyr</i>	1 (0.51)
<i>C. dubliniensis</i>	1 (0.51)
<i>C. trichosporon asahii</i>	1 (0.51)
Others	3 (1.53)

Table 3: Univariate regression analysis for risk factors associated with antifungal resistance candidemia

	Antifungal sensitive (N= 96)	Antifungal resistance (N= 26)	OR (95% CI)	P value
Age (years) Mean± SD	58.7 ± 16.2	56.5 ± 20.29		
Gender, n (%)				
Male	53 (55.21)	10 (38.46)	0.5 (0.2_1.23)	0.12
Female	43 (44.79)	16 (61.54)		
Comorbidities, n (%)				
Diabetes	61 (63.54%)	15 (57.69%)	0.94 (0.77_1.15)	0.58
Hypertension	56 (58.33%)	16 (61.54%)	1.02 (0.85_1.23)	0.76
Chronic Kidney disease	14 (14.58%)	4 (15.38%)	1.01 (0.77_1.32)	0.91
Liver Cirrhosis	10 (10.42%)	4 (15.38%)	1.11(0.78_1.57)	0.48
Cardiovascular disease	44 (45.83)	16 (61.54)	1.14(0.94_1.37)	0.15
Lung diseases	24 (25%)	6 (23.08%)	0.97 (0.79_1.2)	0.83
Solid organ transplantation	2 (2.08%)	2 (7.69%)	1.59 (0.59_4.26)	0.15
Hematological malignancy	2 (2.08%)	0		
Non Hematological malignancy	35 (36.46%)	2 (7.69%)	0.75 (0.65_0.88)	0.004
Neutropenia	7 (7.29%)	4 (15.38%)	1.09 (0.31_3.79)	0.88
History of IV drug user	2 (2.08%)	1 (3.85%)	1.18 (0.52_2.65)	0.6
3-months exposure before candidemia				
Blood/ Platelet transfusion	60 (62.5%)	20 (76.92%)	1.14 (0.95_1.36)	0.16
Recent hospital admission	20 (20.83%)	8 (30.77%)	1.13 (0.87_1.45)	0.28
Broad spectrum antibiotics	90 (93.75%)	26 (100%)	1.28 (1.16_1.42)	0.19
Polyene antifungal	3 (3.13)	0	0.78 (0.71_0.85)	0.36
Azole antifungal (fluconazole)	8 (8.33%)	1 (3.85%)	0.87 (0.68_1.12)	0.43
Echinocandins	19 (19.79%)	12 (46.15%)	1.38 (1.02_1.85)	0.006
Corticosteroids	52 (54.17%)	19 (73.08%)	1.17 (0.98_1.4)	0.08
TPN	13 (13.54%)	4 (15.38%)	1.03 (0.78_1.36)	0.81
Central catheter insertion	71 (73.96%)	21 (80.77%)	1.07 (0.88_1.31)	0.47
Urine catheter	73 (76.04%)	17 (65.38%)	0.88 (0.69_1.12)	0.27
Invasive Ventilation	44 (45.83%)	20 (76.92%)	1.3 (1.08_1.57)	0.005
Previous surgery	38 (39.58%)	14 (53.85%)	1.13 (0.93_1.37)	0.19
GI	21(55.26%)	4 (28.5%)	1.08 (0.88_1.31)	0.42
Non- GI	17 (44.7%)	10 (71.4%)		
Renal Replacement therapy	36 (37.5%)	12 (46.15%)	1.08 (0.88_1.31)	0.42
HD	26 (27.08)	12 (46.15)	1.21 (0.96_1.54)	0.06
PD	3 (3.13)	0		
CRRT	9 (9.38)	0		
SLID	2 (2.08)	2 (7.69)	1.59 (0.59-4.2)	0.15

Odd ratio (OR); Confidence interval (CI); Total parental nutrition (TPN); Gastrointestinal (GI); Hemodialysis (HD); Peritoneal dialysis (PD); Continuous renal replacement therapy (CRRT); Sustained low efficiency dialysis (SLID) N=total number of patients; n=number of patients or events

Table 4: Outcome analysis for patients with antifungal resistance candidemia

	Antifungal sensitive (N= 96)	One or more antifungal resistance (N= 26)	P Value
Length of ICU Stay (n=84), Median (IQR)	18 (6.7 _ 37.5)	29 (12 _ 49)	0.28
Length of hospital stay (days) Median (IQR)	35 (17_ 77)	51.5 (21_ 138)	0.09
Mortality before first negative culture n (%)	26 (27.08)	5 (19.23)	0.41
30-day mortality n (%)	54 (56.25)	15 (57.69)	0.89

Interquartile range (IQR), N=total number of patients; n=number of patients or events

Table 5: Univariate regression analysis for statistically significant risk factors associated with fluconazole resistance *C.parapsilosis* in patients with candidemia

	Fluconazole sensitive <i>C.parapsilosis</i> (N=20)	Fluconazole resistance <i>C.parapsilosis</i> (N=10)	OR (95%CI)	P Value
Previous Echinocandin Exposure	5 (23.81%)	8 (80%)	12.8 (2.01_81.1)	0.005
Blood and Platelet Transfusion	7 (35%)	9 (90%)	14.6 (1.54_138.18)	0.006
Invasive Ventilation	9 (42.8%)	10 (100%)	2.1 (1.31_3.39)	0.004

Odd ratio (OR), N=total number of patients

Additional File Legends

Supplementary Table S1: Resistance pattern among candidemia patients with available susceptibility data by *Candida* isolates

Supplementary Table S2: Resistance pattern among candidemia patients with available susceptibility data by antifungal group

Supplementary Table S3: Multivariate regression analysis for the statistically significant risk factors affecting mortality in patients with antifungal resistance candidemia

Figures




Figure 1

Distribution of *Candida* Species over the study period

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AdditionalFile1.docx](#)